GSK but it is a close call you are talking a sore arm and maybe feeling a bit crummy for a day to gain about 10% efficacy. It's easier to take than shingrix - one dose vs 2 and half dose adjuvant This assumes you don't have much of a difference in terms of waning immunity over time Which would you take?
GSK had a cc this am - I will listen to a replay this weekend However there is some additional data in the presentation, and the efficacy in the 70-79 year old population vs PFE, while not directly comparable bc PFE is >= 2 symtpoms LRTI and GSK is >=2 but can include one upper and one lower LRTI, it is more or less close enough GSK in this age group 93.8 percent efficacy (1 in tx vs 16 in control out of 4.5K in each arm) https://www.gsk.com/media/9614/gsk-rsv-investor-science-event-id-week-2022.pdf (slide 21)
Numbers of events are obviously small, and PFE efficacy definitely quite good, but in the PFE arm the lower bound of the CI comes very close to the regulatory threshold of 20% which might influence regulators and ACIP members BC these are the pt most at risk of complications from LRTI, and you have a 15% delta in efficacy at interim (this could change in time), I would definitely choose GSK over PFE if I were 70 or older
Market Data 
Markets 
AI
